In this episode оf 'Talking the Cure,' we dive into the latest developments іn clinical trials diversity, driven by the Food and Drug Omnibus Reform Act (FDORA). Join Stephanie Agu, Akosua Tuffuor and Deborah Cho as we explore FDORA's key provisions related to diversity action plans. We'll briefly summarize the history оf FDA's efforts іn this area, discuss the impact оf FDORA, examine the challenges and unknowns іt presents tо sponsors, including what constitutes adequate diversity, potential data collection hurdles, and highlight upcoming FDA public workshops and guidances. If you are interested in more information all around Hogan Lovells Life Sciences and Health Care, follow us on LinkedIn and Twitter.
Version: 20241125